What 23,560 peptide buyers taught us about cross-category behavior

The single most underrated insight in DTC health acquisition: the cross-category buyer is not a marginal segment. It's the entire economic engine of a healthy brand.

Across 23,560 transaction-verified peptide buyers, we found 815 customers who purchased from 3 or more product categories — GLP-1 + recovery + hormone, or GLP-1 + cosmetic + ED, etc. That's 3.5% of the audience. They generated a disproportionate share of total revenue.

The lifetime value math

Single-category buyers in our inventory average $215 in documented spend before they exit our visibility window.

Multi-category cross-buyers average $520 — 2.4× higher. They place more orders, spread their spend across more SKUs, and stay engaged longer.

This isn't a Pepleadz-specific finding. Sephora's cross-category beauty buyer is 3× the value of a single-category one. Amazon Prime members spread spend across an order of magnitude more product categories than non-Prime. Costco's $6 rotisserie chicken pulls multi-category basket lifts that fund the entire retail margin.

In peptide DTC, the principle holds. The buyer who started on retatrutide and added BPC-157 for joint recovery and GHK-Cu for skin is signaling something specific: they trust you, and they're willing to consolidate spend.

Why most acquisition strategies miss this

Most lead-vendor pitches segment by "primary intent" — GLP-1 buyer, SARM buyer, hormone buyer. This is correct for surface-level matching but misses the cross-category whales entirely.

A telehealth GLP brand buying "GLP-1 buyers" inventory will get a lot of single-category retatrutide-only customers. That's fine. But the same brand could be buying cross-category whales who've already proven they spread spend — and those convert at 2-3× the standard rate on premium offers.

The price-per-lead difference ($30 standard vs $80 cross-category) is dwarfed by the LTV gap ($215 vs $520).

How to identify cross-category buyers

Pepleadz tags every record by: - Their dominant product category (whichever they bought most) - Their interest_categories array (every category they bought from) - A multi_category boolean flag (3+ categories with documented purchase)

Filter for multi_category = true to isolate this cohort. We have 815 of them in current inventory. Average lifetime spend $520. They cluster in TX (22%), CA (18%), and FL (14%).

The acquisition strategy

If you sell premium subscription offers ($300+/month), the multi-category cohort is your highest-converting audience. Pay the premium. The CAC math works out at first transaction.

If you sell single-product offers, the multi-category cohort still outperforms — because cross-category buyers tend to be early adopters of any new health product. They're the first to try, the most likely to repeat, the loudest in word-of-mouth.

The mistake is thinking they're a niche. They're 3.5% of the audience and disproportionately valuable. They are the audience that funds the rest of your acquisition spend.

Practical next step

If you're running paid acquisition in regulated health, audit your last 1,000 customers. How many bought from 2+ of your product lines? If it's under 5%, you're under-cross-selling. If it's over 15%, you have a real platform forming.

Either way: target the multi-category cohort first when buying acquisition inventory. The math compounds.